Factors affecting HPV vaccine use among recent family medicine residency graduates

Family Medicine

Volumn 45, Issue 2, 2013, Pages 90-94

  Post, Robert E ^a   Carek, Peter J ^b   Mainous, Arch G ^b   Diaz, Vanessa A ^b   Johnson, Sharleen P ^b  

^a Virtua Family Medicine Residency   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; GENERAL PRACTICE; HEALTH CARE SURVEY; HUMAN; MALE; MEDICAL EDUCATION; METHODOLOGY; PAPILLOMAVIRUS INFECTION; QUESTIONNAIRE; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HUMANS; INTERNSHIP AND RESIDENCY; LOGISTIC MODELS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SEX FACTORS; SOUTH CAROLINA;

MLCS; MLOWN;

EID: 84873493903     PISSN: 07423225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2009. Atlanta: US Department of Health and Human Services, 2010.
2. Centers for Disease Control and Prevention. Fact sheet: genital HPV. Updated December 2010. www.cdc.gov/std/hpv/hpv-fact-sheet.pdf. Accessed July 21, 2011.
3. Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant). Merck & Co, Inc, Food and Drug Administration 2009. www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ ucm094042.htm. Accessed July 21, 2011.
4. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and metaanalysis. BMC Infect Dis 2011;Jan 12:11-3.
5. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR 2010;59:630-2.
6. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papilloma-virus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
7. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24.
8. Wong CA, Berkowitz Z, Dorell CG, Price RA, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9to 17-year-old girls: national health interview survey, 2008. Cancer 2011;Jun 20. doi: 10.1002/cncr.26246. [Epub ahead of print]
9. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006;117(5):1486-93.
10. Paul-Ebhohimhen V, Huc S, Tissington H, Oates K, Stark C. HPV vaccination: vaccine acceptance, side effects and screening intentions. Community Pract 2010;83(6):30-3.
11. Wong LP. Young multiethnic women's attitudes toward the HPV vaccine and HPV vaccination. Int J Gynaecol Obstet 2008;103(2):131-5.
12. Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED. Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine 2009;27(30):3945-52.
13. Ferris DG, Waller JL, Miller J, et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med 2009;22(1):34-42.
14. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010;126(3):425-33. Epub 2010 Aug 2.
15. McCave EL. Influential factors in HPV vaccination uptake among providers in four states. J Community Health 2010;35(6):645-52.
16. Centers for Disease Control and Prevention. HPV vaccine-questions and answers. Updated September 15, 2011. www.cdc.gov/vaccines/ vpd-vac/hpv/vac-faqs.htm. Accessed December 8, 2011.
17. Kahn JA, Cooper HP, Vadaparampil ST, et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to12-year-old girls: a statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev 2009;18(8):2325-32.
18. Tan TQ, Bhattacharya L, Gerbie MV. Awareness, perceptions and knowledge of recommended adult vaccines among a nationwide sample of adult primary care providers. J Reprod Med 2011;56(7-8):301-7.
19. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papilloma virus vaccine among family physicians. J Pediatr Adolesc Gynecol 2005;18:391-8.
20. Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008;113(10 Suppl):2841-54.
21. Weiss TW, Zimet GD, Rosenthal SL, Brenneman SK, Klein JD. Human papilloma virus vaccination of males: attitudes and perceptions of physicians who vaccinate females. J Adolesc Health 2010;47(1):3-11. Epub 2010 Apr 21.
22. Centers for Disease Control and Prevention. Press briefing transcript: ACIP recommends all 11-12 year-old males get vaccinated against HPV. www.cdc.gov/media/releases/2011/t1025_hpv_12yroldvaccine.html. Accessed December 5, 2011.